Sarat Chandarlapaty, MD, PhD

home / authors / sarat-chandarlapaty-md-phd

Sarat Chandarlapaty, MD, PhD, is an associate attending medical oncologist and a laboratory head in the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center.

Articles

Amcenestrant’s Potential Role in ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD

September 9th 2021

Sarat Chandarlapaty, MD, offers his opinion on the potential roles amcenestrant could have in the treatment of ER+/HER2- metastatic breast cancer.

AMEERA-1 and ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD

September 9th 2021

Dr Chandarlapaty discusses the AMEERA-1 trial and its impact on the ER+/HER2- metastatic breast cancer landscape.

Amcenestrant and Its Effects on ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD

September 9th 2021

An expert introduces amcenestrant as a potential new therapy for ER+/HER2- metastatic breast cancer and addresses how it differs from current treatment options.

Challenges and Unmet Needs in ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD

September 9th 2021

Dr Chandarlapaty elaborates on the challenges and unmet needs seen when treating ER+/HER2- metastatic breast cancer.

ER+/HER2- Metastatic Breast Cancer and Available Treatment Options

Sarat Chandarlapaty, MD, PhD

September 9th 2021

A medical oncologist discusses the available treatment options for ER+/HER2- metastatic breast cancer.

A Breakdown of ER+/HER2- Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD

September 9th 2021

Sarat Chandarlapaty, MD, gives an overview of ER+/HER2- metastatic breast cancer, including characteristics, diagnosis, and prognosis.

Emerging Therapies in ER+ Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD

July 26th 2016

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering, discusses some of the emerging therapies for patients with ER-positive metastatic breast cancer.